Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $107.00

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its target price raised by equities research analysts at JPMorgan Chase & Co. from $72.00 to $107.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 32.05% from the company’s previous close.

A number of other research firms also recently weighed in on KNSA. Jefferies Financial Group upped their target price on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Citigroup upped their price objective on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a research report on Wednesday. Zacks Research upgraded shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, June 17th. The Goldman Sachs Group boosted their price objective on shares of Kiniksa Pharmaceuticals International from $60.00 to $75.00 and gave the company a “buy” rating in a research report on Thursday, July 23rd. Finally, Wall Street Zen cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 12th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $85.50.

Kiniksa Pharmaceuticals International Trading Up 2.0%

Shares of KNSA stock traded up $1.59 during trading hours on Wednesday, hitting $81.03. 902,299 shares of the company’s stock were exchanged, compared to its average volume of 730,153. Kiniksa Pharmaceuticals International has a 12-month low of $29.66 and a 12-month high of $82.94. The business’s 50 day simple moving average is $57.59 and its 200-day simple moving average is $50.44. The company has a market capitalization of $6.23 billion, a PE ratio of 89.98 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, July 28th. The company reported $0.30 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.30. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The firm had revenue of $243.60 million for the quarter, compared to analysts’ expectations of $226.49 million. Equities analysts anticipate that Kiniksa Pharmaceuticals International will post 1.25 EPS for the current year.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals International news, CEO Sanj K. Patel sold 48,565 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $54.02, for a total transaction of $2,623,481.30. Following the sale, the chief executive officer directly owned 48,565 shares of the company’s stock, valued at $2,623,481.30. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John F. Paolini sold 58,424 shares of the stock in a transaction on Friday, May 1st. The shares were sold at an average price of $53.71, for a total value of $3,137,953.04. Following the sale, the insider owned 65,623 shares in the company, valued at $3,524,611.33. The trade was a 47.10% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 109,130 shares of company stock valued at $5,877,070. 51.98% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Several hedge funds have recently bought and sold shares of KNSA. KBC Group NV purchased a new position in Kiniksa Pharmaceuticals International in the first quarter valued at about $34,000. Smartleaf Asset Management LLC purchased a new stake in shares of Kiniksa Pharmaceuticals International during the fourth quarter valued at about $36,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after buying an additional 532 shares in the last quarter. Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Kiniksa Pharmaceuticals International in the 4th quarter worth approximately $41,000. Finally, CIBC Private Wealth Group LLC bought a new position in shares of Kiniksa Pharmaceuticals International during the 4th quarter worth approximately $41,000. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International News Roundup

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Analysts raised their price targets. Wedbush lifted its target from $72 to $99 and maintained an “outperform” rating, while Citigroup raised its target from $60 to $100 and upgraded or maintained a “buy” rating. The new targets imply roughly 23%–24% potential upside from recent trading levels. Benzinga analyst ratings
• Positive Sentiment: Revenue guidance was increased. Kiniksa now expects 2026 revenue of $980 million to $995 million, above the approximately $940 million consensus estimate. ARCALYST second-quarter net product revenue reached $243.6 million, up about 55% year over year and well ahead of expectations. Kiniksa second-quarter results
• Positive Sentiment: KPL-387 advanced toward pivotal testing. Phase 2 data showed rapid and sustained reductions in pain and inflammation, and the selected 300 mg monthly dose is now being evaluated in an enrolling Phase 3 trial for recurrent pericarditis. KPL-387 pipeline update
• Neutral Sentiment: Profitability was broadly in line. Quarterly EPS of $0.30 matched consensus, although it improved from $0.23 a year earlier; the main earnings catalyst was the substantial revenue beat rather than an EPS surprise. Kiniksa earnings report

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.